( 1 Division of Neurochemistry, Institute of Neurology, and 2 Neurometabolic Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom; 3 Biochemistry Unit, Institute of Child Heath, London, United Kingdom; * address correspondence to this author at: Neurometabolic Unit, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, United Kingdom; fax 44-0-20-7829-1016, e-mail ihargrea@ion.ucl.ac.uk) Coenzyme Q 10 (CoQ 10 ), the predominant ubiquinone species in humans, functions as an electron carrier in the mitochondrial electron transport chain (ETC) and as an intracellular antioxidant (1 ) . Although primary CoQ 10 deficiency is rare, a profound deficiency in skeletal muscle CoQ 10 has been reported in patients with multisystem mitochondrial encephalomyopathies (2, 3 ) . Cardiovascular disease has been associated with a CoQ 10 deficiency (4, 5 ) , and it is becoming increasingly apparent that other groups of patients may become CoQ 10 deficient, particularly individuals with ataxia (6 ) and some patients receiving statins (7 ) .
When assessing tissue CoQ 10 status, we have found that the lack of a commercially available nonphysiologic internal standard (IS) is a major difficulty. Although naturally occurring ubiquinones have been used as ISs in this determination, they are not free from the influence of ubiquinones that might be present in human tissue as the result of dietary contamination (8 ) or synthesis by microorganisms (9, 10 ) . There is a need, therefore, for an alternative IS that is not influenced by exogenous/endogenous ubiquinones. Di-ethoxy-CoQ 10 has been suggested as a nonphysiologic IS to determine CoQ 10 (11 ) . In this study we evaluated this IS along with di-propoxy-CoQ 10 for their suitability to determine tissue CoQ 10 10 status and between skeletal muscle and plasma CoQ 10 status were determined with samples from group 1; correlations between MNC and plasma CoQ 10 status were determined with samples from groups 1 and 2.
The patient with a suspected CoQ 10 deficiency was a 47-year-old female, mentally retarded since birth, ataxic, and with poor vision and hypertrophic cardiomyopathy, in whom evidence of an ETC complex II-III (succinate cytochrome c reductase) deficiency [0.015; reference interval, 0.040 -0.204 (activity expressed as a ratio to citrate synthase activity to allow for mitochondrial enrichment) (12 )] had been detected in skeletal muscle.
MNCs were isolated from 5-10 mL of sodium EDTAanticoagulated blood within 24 h of venesection by use of the ACCUSPIN TM system-Histopaque ® -1077 (SigmaAldrich). The MNCs were suspended in phosphatebuffered saline (150 mmol/L NaCl, 150 mmol/L sodium phosphate), pH 7.2 (200 L per 5 mL of blood), and stored at Ϫ70°C until analysis. During this procedure, plasma was separated from the sodium EDTA-anticoagulated blood and stored at Ϫ70°C until analysis.
Skeletal muscle biopsy homogenates were prepared as described by Heales et al. (12 ) . Protein concentration was determined by the method of Lowry et al. (13 ) . The synthesis of di-ethoxy-CoQ 10 was undertaken as de-scribed by Edlund (11 ) . The synthesis of di-propoxyCoQ 10 was based on the method of Edlund (11 ) , substituting propan-1-ol for ethanol. The concentration of di-propoxy-CoQ 10 was estimated based on the molar absorptivity for CoQ 10 at 275 nm (14.6 ϫ 10
3 ), and the di-propoxy-CoQ 10 was diluted in ethanol to give a final concentration of 1.5 mol/L.
Samples were prepared for HPLC analysis of total CoQ 10 concentration by the addition of IS (30 L) to skeletal muscle (50 L), to MNCs (150 L), and to plasma (200 L) to give a final concentration of 150 nmol/L in the reconstituted extract. The ubiquinones (CoQ 10 and IS) were extracted by the method of Boitier et al. (14 ) . The extracts were evaporated under N 2 and reconstituted in ethanol (300 L). HPLC analysis was performed according to the method of Boitier et al. (14 ) .
CoQ 10 and di-propoxy-CoQ 10 were analyzed at concentrations of 50 mol/L by mass spectrometry using a Quattro micro triple-quadrupole tandem mass spectrometer operating in both the scan and parent ion modes (15 ) .
We used regression analysis to assess the correlation between ultraviolet absorbance (275 nm) and the concentrations of di-propoxy-CoQ 10 and skeletal muscle, MNC, and plasma CoQ 10 , and between age and the MNC, skeletal muscle, and plasma CoQ 10 concentration. The relationship between sex and tissue CoQ 10 concentration was assessed by the Mann-Whitney U-test. Spearman rank correlation coefficients were calculated to assess the association between the CoQ 10 concentrations in skeletal muscle, MNCs, and plasma. A P value Ͻ0.05 was considered significant.
Analysis of the mass spectrum obtained in scan mode for the di-propoxy-CoQ 10 (Fig. 2, A and B, in the online Data Supplement) demonstrated clearly that these impurities were not CoQ 10 analogs, but we were unable to confirm their identities. At the concentration of di-propoxy-CoQ 10 used in tissue determinations (150 nmol/L), these impurities would be undetected on reversed-phase HPLC. Di-propoxy-CoQ 10 is stable during the tissue extraction procedure and can be stored for up to 1 year at Ϫ70°C with no evidence of degradation. Di-ethoxy-CoQ 10 was poorly resolved from CoQ 10 on reversed-phase HPLC (see Fig. 3 in the online Data Supplement), and no further evaluation of this IS was undertaken. In contrast, dipropoxy-CoQ 10 was clearly separated from CoQ 9 and CoQ 10 (Fig. 1) . The ultraviolet absorbance (275 nm) of di-propoxy-CoQ 10 showed linearity (r 2 ϭ 0.999) over the concentration range 0 -1000 nmol/L. Use of this IS (500 nmol/L CoQ 10 added to skeletal muscle homogenate with an endogenous CoQ 10 concentration of 350 nmol/L) gave a mean (SE) recovery of 99.8 (2.9)% (n ϭ 5) of CoQ 10 in the assay. The intraassay CVs for the assessment of CoQ 10 in skeletal muscle, plasma, and MNC samples were 3.4% (mean concentration, 791 nmol/L; n ϭ 6), 4.4% (201 nmol/L; n ϭ 6), and 2.6% (331 nmol/L; n ϭ 5), respectively. The interassay CVs for CoQ 10 determination in skeletal muscle, MNCs, and plasma were 3.1% (861 nmol/L; n ϭ 4), 3.5% (471 nmol/L; n ϭ 5), and 4.5% (760 nmol/L; n ϭ 4), respectively, when the di-propoxyCoQ 10 was used as IS. Detection of CoQ 10 was linear between 10 and 1000 nmol/L in skeletal muscle (r 2 ϭ 0.997), MNCs (r 2 ϭ 0.995), and plasma (r 2 ϭ 0.991). The limit of detection of CoQ 10 was 6 nmol/L for all tissues. Reference intervals for skeletal muscle, MNCs, and plasma were established from the observed range of CoQ 10 concentrations for these tissues ( Table 1 ). The reference intervals for skeletal muscle and plasma were comparable to those reported by Artuch et al. (16 ) and Miles et al. (17 ) for skeletal muscle and plasma, respectively. To our knowledge, there have been no reference intervals for MNC CoQ 10 reported by other laboratories. Age and sex had no significant influence on tissue CoQ 10 concentrations in the reference population, allowing the effect of these variables to be excluded from the study (results not shown). By comparing the reference intervals, we found evidence of a CoQ 10 deficiency in skeletal muscle (33 pmol/mg of protein) and MNCs (20 pmol/mg of protein) in the 47-year-old female patient with low skeletal muscle complex II-III activity.
The decreased CoQ 10 status of MNCs and skeletal muscle from this patient suggested that a relationship might exist between the CoQ 10 status of these tissues, and this prompted us to assess the relationship between skeletal muscle, MNC, and plasma CoQ 10 . We found a close association between skeletal muscle and MNC CoQ 10 concentrations in the 12 disease control patients and in the CoQ 10 -deficient patient (r ϭ 0.89; P Ͻ0.02; n ϭ 13). Exclusion of the CoQ 10 -deficient patient from this correlation did not significantly alter this relationship (r ϭ 0.86; P Ͻ0.02; n ϭ 12). We found no correlation between skeletal muscle and plasma CoQ 10 concentrations (r ϭ 0.015; n ϭ 10) or between MNC and plasma CoQ 10 concentrations (r ϭ 0.21; n ϭ 24).
In conclusion, we have synthesized a di-propoxy-CoQ 10 IS that can be used in CoQ 10 assessment in MNCs, skeletal muscle, and plasma, allowing precision and a good recovery. This IS enabled the establishment of reference intervals for the CoQ 10 concentrations of skeletal muscle, MNCs, and plasma, which has facilitated the identification of a patient with a CoQ 10 deficiency. Bone markers to monitor the efficacy of antiresorptive therapy of osteoporosis are of great value to clinicians. Considerable decreases in markers can be seen within 3 to 6 months after the start of an efficient treatment, with considerable increases in bone mineral density (BMD) 
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